172 results about "Hemagglutinin (influenza)" patented technology

Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.

Glycan arrays that can detect and distinguish between various sub-types and strains of influenza virus are provided. Methods for using the glycan arrays with assays using nanoparticle amplification technique are disclosed. Sandwich assays using gold nanoparticles conjugated to phage particles comprising influenza virus-specific antibodies for detecting multiple serotypes using a single reaction are provided. Plurality of glycans directed to specific target HA of influenza virus comprises the array. Detector molecules comprising noble metals conjugated to (a) phage display particles expressing antibodies against hemagglutinin and (b) neuraminidase binding agents are disclosed.

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided.

Disclosed is a method for increasing vaccine potency whereby a subject's immune system is first primed with an Ii-Key hybrid peptide construct before the subject subsequently receives a vaccine for a pathogen of interest. The vaccine may be comprised of a protein or portion thereof that is encoded by the genome of the pathogen. The vaccine may also be a DNA vaccine comprised of DNA encoding a protein of the pathogen. The Ii-Key hybrid peptide construct includes the LRMK residues of Ii-Key protein and an MHC Class II epitope of the protein or portion thereof which is used in the vaccine. The Ii-Key construct may be administered in the form of a nucleic acid construct encoding the Ii-Key hybrid peptide. Priming with Ii-Key peptides enhances the immunogenicity of rHA protein and HA and HIV DNA vaccines. Methods are described relating to the use of Ii-Key hybrid constructs in vaccine protocols wherein the pathogen is HIV or Influenza A, including H5N1. Methods and compositions are described wherein the MHC Class II epitope of the Ii-Key hybrid is hemagglutinin encoded by Influenza A or the Gag protein encoded by HIV.

A method of immunoassay of H5 subtype influenza A virus by which the virus can be accurately assayed even in cases where a certain level of mutation has occurred in the H5 subtype influenza A virus, and a kit therefor, and a novel anti-H5 subtype influenza A virus monoclonal antibody which can be used for the immunoassay are disclosed. The antibody or an antigen-binding fragment thereof of the present invention undergoes antigen-antibody reaction with hemagglutinin of H5 subtype influenza A virus, and the corresponding epitope of the antibody or an antigen-binding fragment thereof is located in a region other than the receptor subdomain (excluding C-terminal region thereof consisting of 11 amino acids), which antibody or an antigen-binding fragment thereof does not have neutralizing activity against the influenza A virus.

Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.

Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.

Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 μg influenza virus strain per ml. Components (i) and (ii) can be presented in kit form.

The application relates to an anti-H7N9 full human derived monoclonal antibody hIg311 and a preparation method and application thereof. A memory B cell PCR method is used for quickly screening a fullhuman derived monoclonal antibody hIg311, and the anti-H7N9 human derived monoclonal antibody hIg311 is free from any mouse derived components. The antibody disclosed by the application can realize target combination of hemagglutinin HA of H7N9 viruses, and has notable anti H7N9 viral infection neutralization activity. The antibody disclosed by the application does not generate toxic and side effects for resisting mouse resisting antibodies, has good biocompatibility, and is suitable for becoming and has potential to become macromolecular drugs for treating influenza viruses.

The invention discloses an influenza A virus Vero cell adapted strain and application thereof. The influenza A virus Vero cell adapted strain is named as A/Yunnan/1/2005Va(H3N2), and the preserving number of the strain is CCTCC NO:V200514. The strain comprises an H3 subgroup hemagglutinin gene, an N2 subgroup neuraminidase gene and 6 internal genes for high yield of characteristic influenza viruses on Vero cells. The blood coagulation titer can be maintained at more than 1,024 by continuous subculturing of the strain on the Vero cells. The strain can be taken as a donor strain and subjected to genetic reassortment with an epidemic strain, or reverse genetics technology is adopted to perform genetic reassortment on the 6 internal genes and 2 surface protein genes of the epidemic strain to obtain the Vero cell adapted strain of the epidemic strain, and finally the adapted strain is used for preparing a Vero cell influenza vaccine or a Vero cell pandemic influenza vaccine.

Pharmaceutical and vaccine compositions comprise recombinant hemagglutinin from a pre-pandemic or pandemic influenza virus and an adjuvant comprising GLA. A particularly relevant pre-pandemic influenza virus is H5N1. Kits and methods of using the compositions are also provided.